MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial

Alzheimers Dement. 2024 Jun;20(6):3852-3863. doi: 10.1002/alz.13830. Epub 2024 Apr 17.

Abstract

Introduction: Cerebral small vessel disease (SVD) is a common cause of stroke/vascular dementia with few effective treatments. Neuroinflammation and increased blood-brain barrier (BBB) permeability may influence pathogenesis. In rodent models, minocycline reduced inflammation/BBB permeability. We determined whether minocycline had a similar effect in patients with SVD.

Methods: MINERVA was a single-center, phase II, randomized, double-blind, placebo-controlled trial. Forty-four participants with moderate-to-severe SVD took minocycline or placebo for 3 months. Co-primary outcomes were microglial signal (determined using 11C-PK11195 positron emission tomography) and BBB permeability (using dynamic contrast-enhanced MRI).

Results: Forty-four participants were recruited between September 2019 and June 2022. Minocycline had no effect on 11C-PK11195 binding (relative risk [RR] 1.01, 95% confidence interval [CI] 0.98-1.04), or BBB permeability (RR 0.97, 95% CI 0.91-1.03). Serum inflammatory markers were not affected.

Discussion: 11C-PK11195 binding and increased BBB permeability are present in SVD; minocycline did not reduce either process. Whether these pathophysiological mechanisms are disease-causing remains unclear.

International clinical trials registry portal identifier: ISRCTN15483452 HIGHLIGHTS: We found focal areas of increased microglial signal and increased blood-brain barrier permeability in patients with small vessel disease. Minocycline treatment was not associated with a change in these processes measured using advanced neuroimaging. Blood-brain barrier permeability was dynamic but MRI-derived measurements correlated well with CSF/serum albumin ratio. Advanced neuroimaging is a feasible outcome measure for mechanistic clinical trials.

Keywords: blood‐brain barrier; cerebral small vessel disease; neuroinflammation; vascular cognitive impairment; vascular dementia.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood-Brain Barrier* / drug effects
  • Blood-Brain Barrier* / metabolism
  • Cerebral Small Vessel Diseases* / diagnostic imaging
  • Cerebral Small Vessel Diseases* / drug therapy
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation / drug therapy
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Minocycline* / pharmacology
  • Positron-Emission Tomography*

Substances

  • Minocycline

Associated data

  • ISRCTN/ISRCTN15483452